This has been done after receiving approval of the Competition Commission of India and completion of all the necessary formalities for closure of the transaction, Sun Pharmaceutical Industries said in a filing to BSE.
On July 27, 2016 Sun Pharma had informed the bourses that it had signed an agreement with RPG Life Sciences to divest seven prescription brands in India, owned by the company and its subsidiary, for a consideration of Rs 41 crore.
The seven divested brands include those used for treatment of respiratory-track infections, urological disorders, cardiovascular diseases and brands in health supplements segment, it had added.